Product Information

CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.2858 per EA under NDC 62332074431. Its NADAC has been published 144 times since Feb 21, 2024.

FDA first approved this application on Sep 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CHLORDIAZEPOXIDE-CLIDINIUM CAP

Chlordiazepoxide hydrochloride and clidinium bromide
$0.2858per EA
DEA Schedule CIV

Strength

5; 2.5 mg/1; mg/1

NDC

62332074431

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA216969

FDA Approved

9/15/2023

TE Code

AB

On Market Since

10/4/2023

Pharmacological Classes

Anticholinergic
Benzodiazepine
Benzodiazepines
Cholinergic Antagonists
Decreased Parasympathetic Acetylcholine Activity
Digestive/GI System Activity Alteration
GI Motility Alteration

Price Statistics

The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 144 times since Feb 21, 2024, and over the history we have for it it has declined 23.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.2858 per EA
All-time high$0.5272 (Oct 16, 2024)
All-time low$0.2405 (Mar 18, 2026)
52-week high$0.2858
52-week low$0.2405
Median price$0.2844
Average price$0.3023
Largest weekly change+78.0% (Aug 21, 2024)
Weeks tracked144
Tracking sinceFeb 21, 2024

Price History

1W

+3.6%

1M

+3.6%

3M

+12.3%

6M

+5.3%

1Y

+15.2%

3Y

N/A

5Y

N/A

All

-23.4%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Chlordiazepoxide hydrochloride and clidinium bromide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?

The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Alembic Pharmaceuticals Inc., is $0.2858 per EA (NDC 62332074431), effective Nov 18, 2026.

How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?

Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has declined 23.4%. It has been tracked across 144 weekly CMS publications since Feb 21, 2024.

What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?

Since Feb 21, 2024, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2405 (Mar 18, 2026) to a high of $0.5272 (Oct 16, 2024), with a median of $0.2844 per EA.

Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?

No other NADAC-published product currently shares the active ingredient and strength of CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?

CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 62332074431) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.